Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903)

INTRODUCTION: Osimertinib is an effective therapy in EGFR mutant NSCLC, but resistance invariably develops. Navitoclax is an oral inhibitor of BCL-2/BCL-xL that has exhibited synergy with osimertinib in preclinical models of EGFR-mutant NSCLC. In hematologic malignancies, BCL-2 family inhibitors in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Bertino, Erin M., Gentzler, Ryan D., Clifford, Sarah, Kolesar, Jill, Muzikansky, Alona, Haura, Eric B., Piotrowska, Zofia, Camidge, D. Ross, Stinchcombe, Thomas E., Hann, Christine, Malhotra, Jyoti, Villaruz, Liza C., Paweletz, Cloud P., Lau, Christie L., Sholl, Lynette, Takebe, Naoko, Moscow, Jeffrey A., Shapiro, Geoffrey I., Jänne, Pasi A., Oxnard, Geoffrey R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7976451/
https://ncbi.nlm.nih.gov/pubmed/33376097
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-4084
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky